FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology. Described is the plasmid pVBL-RBDomik containing the nucleotide sequence encoding the SARS-CoV-2 RBD protein line B.1.1.529 and providing expression of this RBD protein in mammalian cells and further purification by affinity chromatography. At the same time, the resulting RBD protein is intended for the direct production of a vaccine preparation against SARS-CoV-2-line B.1.1.529.
EFFECT: invention can be used to obtain the RBD protein - the recombinant structural domain of the spike glycoprotein of the Sarbecovirus SARS-CoV-2-line B.1.1.529.
1 cl, 1 dwg, 1 tbl, 4 ex
Authors
Dates
2022-05-26—Published
2021-12-13—Filed